ADC Historical Income Statement

ADCT Stock

USD 2.26 0.04 1.80%

Historical analysis of ADC Therapeutics income statement accounts such as Depreciation And Amortization of 2.7 M, Interest Expense of 48.6 M or Selling General Administrative of 57.9 M can show how well ADC Therapeutics SA performed in making a profits. Evaluating ADC Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of ADC Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining ADC Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether ADC Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ADC Therapeutics SA. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

About ADC Income Statement Analysis

ADC Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to ADC Therapeutics shareholders. The income statement also shows ADC investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

ADC Therapeutics Income Statement Chart

At this time, ADC Therapeutics' Interest Expense is comparatively stable compared to the past year. Selling General Administrative is likely to gain to about 57.9 M in 2024, whereas Interest Income is likely to drop slightly above 5 M in 2024.

Selling General Administrative Other Operating Expenses Research Development Cost Of Revenue Net Income

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of ADC Therapeutics. It is also known as ADC Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Cost Of Revenue

Cost of Revenue is found on ADC Therapeutics income statement and represents the costs associated with goods and services ADC Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in ADC Therapeutics financial statement analysis. It represents the amount of money remaining after all of ADC Therapeutics SA operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Most accounts from ADC Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into ADC Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ADC Therapeutics SA. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	2.6M	2.4M	3.3M	2.7M
Interest Income	66K	18.0M	6.6M	5.0M

Depreciation And Amortization Interest Income

ADC Therapeutics income statement Correlations

	Tax Provision	Net Interest Income	Interest Income	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Reconciled Depreciation	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Selling And Marketing Expenses
Tax Provision		0.38	0.17	-0.25	-0.25	-0.28	-0.05	-0.09	-0.5	0.74	0.56	0.66	-0.41	0.66	0.47	-0.51	-0.49	0.61	-0.22	0.49	0.26	-0.56
Net Interest Income	0.38		-0.5	-0.5	-0.98	-0.61	-0.58	-0.61	-0.75	0.57	0.64	0.49	-0.66	0.48	0.83	-0.74	-0.79	0.69	0.71	0.82	-0.72	-0.87
Interest Income	0.17	-0.5		0.33	0.66	0.77	0.97	0.84	0.67	-0.04	-0.22	0.02	0.69	0.03	-0.46	0.66	0.5	-0.21	-0.71	-0.27	0.31	0.67
Depreciation And Amortization	-0.25	-0.5	0.33		0.46	0.45	0.34	-0.01	0.55	-0.52	-0.55	-0.5	0.57	-0.47	-0.41	0.56	0.78	-0.55	-0.35	-0.58	0.28	0.49
Interest Expense	-0.25	-0.98	0.66	0.46		0.67	0.71	0.73	0.76	-0.46	-0.56	-0.37	0.7	-0.36	-0.79	0.76	0.74	-0.6	-0.77	-0.74	0.72	0.89
Selling General Administrative	-0.28	-0.61	0.77	0.45	0.67		0.85	0.78	0.95	-0.6	-0.73	-0.56	0.95	-0.55	-0.84	0.95	0.8	-0.71	-0.73	-0.67	0.11	0.8
Total Revenue	-0.05	-0.58	0.97	0.34	0.71	0.85		0.9	0.78	-0.19	-0.33	-0.11	0.77	-0.1	-0.6	0.77	0.58	-0.33	-0.68	-0.36	0.23	0.79
Gross Profit	-0.09	-0.61	0.84	-0.01	0.73	0.78	0.9		0.71	-0.19	-0.33	-0.11	0.68	-0.11	-0.65	0.71	0.44	-0.33	-0.68	-0.37	0.27	0.77
Other Operating Expenses	-0.5	-0.75	0.67	0.55	0.76	0.95	0.78	0.71		-0.76	-0.83	-0.7	0.97	-0.69	-0.89	1.0	0.91	-0.84	-0.65	-0.81	0.17	0.91
Operating Income	0.74	0.57	-0.04	-0.52	-0.46	-0.6	-0.19	-0.19	-0.76		0.96	0.99	-0.73	0.99	0.77	-0.77	-0.83	0.97	0.33	0.9	-0.04	-0.61
Net Income From Continuing Ops	0.56	0.64	-0.22	-0.55	-0.56	-0.73	-0.33	-0.33	-0.83	0.96		0.96	-0.82	0.96	0.86	-0.84	-0.89	0.99	0.55	0.95	-0.17	-0.64
Ebit	0.66	0.49	0.02	-0.5	-0.37	-0.56	-0.11	-0.11	-0.7	0.99	0.96		-0.68	1.0	0.73	-0.71	-0.79	0.96	0.33	0.88	-0.02	-0.5
Research Development	-0.41	-0.66	0.69	0.57	0.7	0.95	0.77	0.68	0.97	-0.73	-0.82	-0.68		-0.67	-0.8	0.97	0.87	-0.81	-0.66	-0.77	0.15	0.84
Ebitda	0.66	0.48	0.03	-0.47	-0.36	-0.55	-0.1	-0.11	-0.69	0.99	0.96	1.0	-0.67		0.73	-0.7	-0.78	0.96	0.32	0.88	-0.01	-0.49
Cost Of Revenue	0.47	0.83	-0.46	-0.41	-0.79	-0.84	-0.6	-0.65	-0.89	0.77	0.86	0.73	-0.8	0.73		-0.89	-0.85	0.87	0.73	0.89	-0.36	-0.82
Total Operating Expenses	-0.51	-0.74	0.66	0.56	0.76	0.95	0.77	0.71	1.0	-0.77	-0.84	-0.71	0.97	-0.7	-0.89		0.92	-0.84	-0.65	-0.81	0.17	0.91
Reconciled Depreciation	-0.49	-0.79	0.5	0.78	0.74	0.8	0.58	0.44	0.91	-0.83	-0.89	-0.79	0.87	-0.78	-0.85	0.92		-0.9	-0.64	-0.9	0.33	0.81
Income Before Tax	0.61	0.69	-0.21	-0.55	-0.6	-0.71	-0.33	-0.33	-0.84	0.97	0.99	0.96	-0.81	0.96	0.87	-0.84	-0.9		0.53	0.97	-0.21	-0.68
Total Other Income Expense Net	-0.22	0.71	-0.71	-0.35	-0.77	-0.73	-0.68	-0.68	-0.65	0.33	0.55	0.33	-0.66	0.32	0.73	-0.65	-0.64	0.53		0.66	-0.68	-0.57
Net Income	0.49	0.82	-0.27	-0.58	-0.74	-0.67	-0.36	-0.37	-0.81	0.9	0.95	0.88	-0.77	0.88	0.89	-0.81	-0.9	0.97	0.66		-0.45	-0.71
Income Tax Expense	0.26	-0.72	0.31	0.28	0.72	0.11	0.23	0.27	0.17	-0.04	-0.17	-0.02	0.15	-0.01	-0.36	0.17	0.33	-0.21	-0.68	-0.45		0.33
Selling And Marketing Expenses	-0.56	-0.87	0.67	0.49	0.89	0.8	0.79	0.77	0.91	-0.61	-0.64	-0.5	0.84	-0.49	-0.82	0.91	0.81	-0.68	-0.57	-0.71	0.33

Click cells to compare fundamentals

ADC Therapeutics Account Relationship Matchups

ADC Therapeutics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Tax Provision	582K	327K	(21.5M)	1.1M	(3.0M)	(3.1M)
Net Interest Income	2.1M	(4.1M)	(18.3M)	(19.0M)	(39.6M)	(37.6M)
Interest Income	2.3M	832K	66K	18.0M	6.6M	5.0M
Depreciation And Amortization	5.6M	2.0M	2.6M	2.4M	3.3M	2.7M
Interest Expense	156K	4.9M	18.3M	36.9M	46.3M	48.6M
Selling General Administrative	13.8M	77.2M	71.5M	141.1M	48.4M	57.9M
Total Revenue	2.3M	0.0	33.9M	209.9M	69.6M	50.1M
Gross Profit	(105.2M)	(2.0M)	32.5M	205.3M	67.0M	70.4M
Other Operating Expenses	121.7M	219.3M	295.6M	333.5M	235.5M	224.1M
Operating Income	(119.4M)	(219.3M)	(261.7M)	(123.6M)	(166.0M)	(174.3M)
Net Income From Continuing Ops	(116.5M)	(246.3M)	(230.0M)	(155.8M)	(178.5M)	(187.4M)
Ebit	(119.4M)	(221.2M)	(226.3M)	(110.4M)	(150.0M)	(157.5M)
Research Development	107.5M	142.0M	158.0M	187.9M	127.1M	145.6M
Ebitda	(113.8M)	(219.3M)	(223.7M)	(108.1M)	(146.8M)	(154.1M)
Cost Of Revenue	107.5M	2.0M	1.4M	4.6M	2.5M	2.4M
Total Operating Expenses	121.7M	219.3M	294.2M	329.0M	233.0M	222.8M
Reconciled Depreciation	1.6M	2.2M	2.6M	2.3M	2.8M	2.0M
Income Before Tax	(115.9M)	(246.0M)	(251.5M)	(154.7M)	(195.4M)	(205.2M)
Total Other Income Expense Net	3.5M	(26.7M)	10.2M	(33.6M)	(29.4M)	(28.0M)
Net Income Applicable To Common Shares	(116.5M)	(246.3M)	(230.0M)	(155.8M)	(140.2M)	(147.2M)
Net Income	(116.5M)	(246.3M)	(230.0M)	(155.8M)	(240.1M)	(252.1M)
Income Tax Expense	582K	327K	(21.5M)	1.1M	39.1M	41.1M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for ADC Stock Analysis

When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ADC Historical Income Statement

About ADC Income Statement Analysis

ADC Therapeutics Income Statement Chart

Other Operating Expenses

Cost Of Revenue

Net Income

ADC Therapeutics income statement Correlations

ADC Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ADC Therapeutics income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for ADC Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebitda	+ 1.0	Ebit
Ebit	+ 0.99	Operating Income
Ebitda	+ 0.99	Operating Income
Income Before Tax	+ 0.99	Net Income From Continuing Ops
Total Revenue	+ 0.97	Interest Income

Interest Expense	- 0.98	Net Interest Income
Net Income	- 0.9	Reconciled Depreciation
Income Before Tax	- 0.9	Reconciled Depreciation
Total Operating Expenses	- 0.89	Cost Of Revenue
Reconciled Depreciation	- 0.89	Net Income From Continuing Ops
Cost Of Revenue	- 0.89	Other Operating Expenses